feed,title,long_url,short_url
Benzinga,"Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss",https://benzinga.com/general/biotech/23/10/35520480/uphill-battle-ahead-for-gene-therapy-player-sarepta-analysts-lower-price-targets-following-duchen,https://da.gd/JYCCqg
Benzinga,Healthcare Service Provider Tenet Healthcare's Q3 Earnings Beat On Higher Volumes; Tightens Guidance,https://benzinga.com/news/earnings/23/10/35512827/healthcare-service-provider-tenet-healthcares-q3-earnings-beat-on-higher-volumes-tightens-guidance,https://da.gd/GdTI2f
